Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis

Journal of Internal Medicine

Volumn 247, Issue 3, 2000, Pages 371-380

  Palinski, Wulf ^a   Witztum, J L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Arteriosclerosis; Autoantibodies; Immune system; Oxidized lipoproteins; Phospholipids; T cells

Indexed keywords

ANTIGEN; AUTOANTIBODY; EPITOPE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY;

ATHEROGENESIS; ATHEROSCLEROSIS; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; LIPID PEROXIDATION; NONHUMAN; OXIDATION; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ARTERIOSCLEROSIS; AUTOANTIBODIES; CHOLESTEROL, LDL; EPITOPES; HUMANS; LIPID PEROXIDATION; PHOSPHOLIPIDS; T-LYMPHOCYTES;

EID: 0034035885     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00656.x     Document Type: Conference Paper

References (83)

1. 1 Libby P, Hansson GK, Pober JS. Atherogenesis and inflammation. In: Chien KR, ed. Molecular Basis of Cardiovascular Disease. Philadelphia: WB Saunders, 1999; 349-66.
2. 2 Steinberg D, Witztum JL. Lipoproteins, lipoprotein oxidation, and atherogenesis. In: Chien KR, ed. Molecular Basis of Cardiovascular Disease. Philadelphia: WB Saunders, 1999; 458-75.
3. 3 Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
4. 4 Ylä-Herttuala S. Is oxidized low-density lipoprotein present in vivo? Curr Opin Lipidol 1998; 9: 337-44.
5. 5 Ricote M, Huang J, Fajas L et al. Expression of the peroxisome proliferator-activated receptor γ in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614-19.
6. 6 Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad Biol Chem 1991; 11: 81-128.
7. 7 Curtiss LK, Witztum JL. A novel method for generating region specific monoclonal antibodies to modified proteins: application to the identification of human glucosylated low density lipoproteins. J Clin Invest 1983; 72: 1427-38.
8. 8 Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation or carbamylation. Generation of antibodies specific for derivatized lysine. J Lipid Res 1984; 25: 1109-16.
9. 9 Palinski W, Rosenfeld ME, Ylä-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-76.
10. 10 Palinski W, Ylä-Herttuala S, Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325-35.
11. 11 Ylä-Herttuala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
12. 12 Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 10: 336-49.
13. 13 Palinski W, Ord V, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994; 14: 605-16.
14. 14 Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114: 383-87.
15. 15 Orekhov AN, Tertov VV, Kabakov AE, Adamova IYU, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb 1991; 11: 316-26.
16. 16 Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized low density lipoprotein in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1569-76.
17. 17 Salonen JT, Ylä-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-87.
18. 18 Maggi E, Finardi G, Poli M et al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993; 4: 1119-22.
19. 19 Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Antioxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Intl J Clin Lab Res 1993; 23: 95-101.
20. 20 Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Pre-eclampsia and serum antibodies to oxidised low density lipoprotein. Lancet 1994; 343: 645-46.
21. 21 Maggi E, Chiesa R, Melissano G et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994; 14: 1892-99.
22. 22 Puurunen M, Mänttäri M, Manninen V et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-609.
23. 23 Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15: 441-45.
24. 24 Heitzer T, Ylä-Herttuala S, Luoma J et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996; 93: 1346-53.
25. 25 Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. J Am Med Assoc 1999; 281: 1718-21.
26. 26 Palinski W, Hörkkö S, Miller E et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800-14.
27. 27 Itabe H, Yamamoto H, Imanaka T et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37: 45-53.
28. 28 Holvoet P, Collen D. Beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17: 2376-82.
29. 29 Lopes-Virella MF, Virella G, Orchard TJ et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999; 90: 165-72.
30. 30 Palinski W, Miller E, Witztum JL. Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-25.
31. 31 Ameli S, Hultgårdth-Nilsson A, Regnström J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-79.
32. 32 Nilsson J, Calara F, Regnström J et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1997; 30: 1886-91.
33. 33 George J, Afek A, Gilburd B et al. Hyperimmunization of apoE-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-52.
34. 34 Freigang S, Hörkkö S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-82.
35. 35 Hansson GK, Holm J, Holm S, Fotev Z, Hedric HJ, Fingerle J. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA 1991; 88: 10 530-34.
36. 36 Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995; 96: 1389-94.
37. 37 Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am J Pathol 1993; 142: 1906-15.
38. 38 Fyfe AI, Qiao JH, Lusis AJ. Immune deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 1994; 94: 2516-20.
39. 39 Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-203.
40. 40 Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102: 910-18.
41. 41 Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997; 100: 550-57.
42. 42 Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-61.
43. 43 Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 1996; 271: 26 174-78.
44. 44 Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1997; 94: 4642-46.
45. 45 Daugherty A, Puré E, Delfel-Butteiger D et al. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/-mice. J Clin Invest 1997; 100: 1575-80.
46. 46 Tanaka H, Swanson SJ, Sukhova G, Schoen FJ, Libby P. Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-alpha and proliferate during acute rejection of rabbit cardiac allografts. Am J Pathol 1995; 147: 617-26.
47. 47 Shi C, Lee WS, He Q et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051-56.
48. 48 Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-68.
49. 49 Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
50. 50 Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-97.
51. 51 Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353-63.
52. 52 Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998; 141: 1-15.
53. 53 Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997; 8: 301-11.
54. 54 Terkeltaub R, Boisvert VA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998; 9: 397-405.
55. 55 Abraham R, Choudhury A, Basu SK, Bal V, Rath S. Disruption of T cell tolerance by directing a self antigen to macrophage-specific scavenger receptors. J Immunol 1997; 158: 4029-35.
56. 56 Ylä-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized low density lipoprotein. Arterioscler Thromb 1994; 14: 32-40.
57. 57 Roselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populations in atherosclerotic lesions of apoE -/-and LDL receptor -/-mice. Decreasing density with disease progression. Arterioscler Thromb Vasc Biol 1996; 16: 1013-18.
58. 58 Stemme S, Faber B, Holm J, Bondjers G, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-97.
59. 59 Constant SL, Bottomly K. Induction of Th1 and Th2, CD4+ T-cell responses: the alternative approaches. Annu Rev Immunol 1997; 15: 297-322.
60. 60 Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL) -12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-38.
61. 61 Zhou X, Paulsson G, Stemme SD, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apoE-knock-out mice. J Clin Invest 1998; 101: 1717-25.
62. 62 Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 1997; 8: 174-80.
63. 63 Palinski W, Koschinsky T, Butler SW et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 571-82.
64. 64 Reaven P, Merat S, Casanada F, Sutphin M, Palinski W. Effect of streptozotocin induced hyperglycemia on lipid profiles, formation of advanced glycation end products in lesions and extent of atherosclerosis in LDL receptor deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 2250-56.
65. 65 Xu Q, Dietrich H, Steiner HJ et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-99.
66. 66 Xu Q, Kleindienst R, Schett G et al. Regression of arteriosclerotic lesions induced by immunization with heat shock protein 65-containing material in normocholesterolemic, but not hypercholesterolemic, rabbits. Atherosclerosis 1996; 123: 145-55.
67. 67 Hörkkö S, Miller E, Itabe H et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103: 117-28.
68. 68 Watson AD, Leitinger N, Navab M et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272: 13 597-607.
69. 69 Suzuki H, Kurihara Y, Takeya M et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-96.
70. 70 Hörkkö S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815-25.
71. 2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci USA 1997; 94: 10 356-61.
72. 72 Vaarala O, Määttäri M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27.
73. 73 Heery JM, Kozak M, Stafforini DM et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995; 96: 2322-30.
74. 74 Pierangeli SS, Goldsmith GH, Branch DW, Harris EN. Antiphospholipid antibody: functional specificity for inhibition of prothrombin activation by the prothrombinase complex. Br J Haematol 1997; 97: 768-74.
75. 75 Napoli C, D'Armiento FP, Mancini FP, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of LDL and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 110: 2680-90.
76. 76 Napoli C, Witztum JL, DeNigris F, Palumbo G, D'Armiento FP, Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation 1999; 99: 2003-10.
77. 77 Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999; 354: 1234-41.
78. 78 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-25.
79. 79 Amara A, Constans J, Chaugier C et al. Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clin Exp Immunol 1995; 101: 233-38.
80. 80 Savolainen A, von Essen R, Leikola J et al. Antibodies against oxidised low-density lipoprotein in juvenile chronic arthritis. Scand J Rheumatol 1995; 24: 209-11.
81. 81 Itabe H, Takeshima E, Iwasaki H et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994; 269: 15 274-79.
82. 82 Tsimikas S, Palinski W, Halpern SA, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999; 6: 41-53.
83. 83 Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000; 20: 689-697.